Edwards Lifesciences Corporation $EW Shares Sold by California Public Employees Retirement System

California Public Employees Retirement System reduced its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 2.6% in the 1st quarter, Holdings Channel reports. The fund owned 976,943 shares of the medical research company’s stock after selling 26,580 shares during the period. California Public Employees Retirement System’s holdings in Edwards Lifesciences were worth $78,234,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of EW. Hanson & Doremus Investment Management purchased a new stake in Edwards Lifesciences in the 1st quarter worth approximately $25,000. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $25,000. MV Capital Management Inc. acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $26,000. Kemnay Advisory Services Inc. purchased a new stake in Edwards Lifesciences during the fourth quarter worth $27,000. Finally, Kohmann Bosshard Financial Services LLC purchased a new stake in Edwards Lifesciences during the fourth quarter worth $28,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares in the company, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 45,577 shares of company stock valued at $3,855,527 over the last quarter. 0.31% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on EW. Truist Financial lifted their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a report on Thursday. Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. BTIG Research lifted their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Finally, TD Cowen reaffirmed a “buy” rating and set a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a research note on Tuesday, June 2nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.95.

Edwards Lifesciences Stock Down 0.0%

EW stock opened at $85.72 on Monday. The stock has a market capitalization of $49.36 billion, a P/E ratio of 45.60, a P/E/G ratio of 2.15 and a beta of 0.86. The firm has a 50-day simple moving average of $87.34 and a 200-day simple moving average of $83.92. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. The firm had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. Edwards Lifesciences’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period last year, the company posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.